How Iron Bisglycinate Works: Mechanisms of Action

1. Executive mechanism summary

Iron bisglycinate works by delivering iron, an essential mineral, to the body. Once the iron is absorbed, it follows the same routes as iron from any other source. It is carried in the blood by the protein transferrin, taken up by cells, used to make hemoglobin and iron-containing enzymes, and stored as ferritin. The mechanisms that make iron bisglycinate different from other iron supplements all concern the first step, absorption, and the events in the gut.

Iron bisglycinate is a chelate, meaning an iron (II) ion held by two glycine molecules. Researchers have proposed that this structure helps iron survive the stomach and intestine, that it may be less bound by inhibitors such as phytate and polyphenols, and that it may be gentler on the gut lining. These ideas have partial support from laboratory, animal and human absorption studies, but they are not fully proven. Human trials show that iron bisglycinate raises iron stores, and some suggest it does so at lower doses than ferrous sulfate. How exactly that happens is still debated.

In short: the biology of iron after absorption is well established, while the special properties of the bisglycinate chelate are plausible hypotheses with moderate-to-limited human evidence. This page separates the two. It is educational and is not medical advice.

2. Key active compounds

Three components matter in an iron bisglycinate supplement.

•      Ferrous iron (Fe2+): The active nutrient. The body can only use iron once it has entered cells, and the ferrous form is the one that transporters in the gut recognize.

•      Glycine: The amino acid that forms the chelate. It acts as a carrier. At supplement doses it provides only tens of milligrams of glycine, so any effect of glycine as a nutrient or neurotransmitter is not expected.

•      The chelate complex itself: The ring-shaped structure in which each glycine binds iron through its nitrogen and oxygen atoms. Its stability determines how much iron is released at which point in the gut. Some research suggests the chelate is stable across a range of acidity, but it does not remain intact forever and will dissociate to some extent.

Many products add vitamin C, which keeps iron in the ferrous state and improves absorption, and some add other minerals or B vitamins. These additions alter the mechanism in practice and should be considered separately from the iron form.

3. Primary biological targets

Iron bisglycinate does not work by binding a single receptor, as a drug would. Instead, it feeds iron into a system of transporters, storage proteins and enzymes that the body already uses to handle iron. The main targets are listed below.

Target	Role	Relevance to iron supplements
Duodenal enterocytes (DMT1, ferroportin)	Take up and export dietary iron	Main site where form, dose and food affect absorption
Transferrin in plasma	Carries iron in the blood	Delivers absorbed iron to tissues
Bone marrow red cell precursors (TfR1)	Use iron to make heme and hemoglobin	Site of the main clinical response to iron
Liver (ferritin, hepcidin)	Stores iron and sets the body supply	Controls how much more iron is absorbed
Macrophages	Recycle iron from old red cells and store iron	Hold iron during inflammation
Iron-dependent enzymes and mitochondria	Energy production, DNA synthesis, neurotransmitter synthesis	Link iron status to fatigue and function
Gut lumen and microbiome	Meet unabsorbed iron	Possible source of side effects

 

This is why the effect of an iron supplement depends so much on the person's starting point. In someone with low iron, the body increases transporters and lowers hepcidin, so more iron is absorbed. In someone with full stores, the same dose is largely blocked.

4. Pathway 1: Intestinal absorption

The first pathway is absorption in the duodenum and upper jejunum, which is where most iron enters the body. For ordinary non-heme iron, the sequence is well known. Ferric iron is reduced to ferrous iron at the surface of the intestinal cell by an enzyme called duodenal cytochrome b. Ferrous iron then crosses the membrane through divalent metal transporter 1 (DMT1), which works best in the mildly acidic environment at the top of the small intestine.

Iron bisglycinate may enter this system in two ways. The first, and best supported, is dissociation. The chelate releases ferrous iron at the cell surface or in the lumen, and the iron enters through DMT1 like iron from a salt. Evidence for this includes the finding that absorption from bisglycinate rises in people with low iron stores and falls in people with high stores, which is a behavior typical of regulated, DMT1-type absorption.

The second is uptake of the intact chelate through amino acid or small peptide transporters. This idea is attractive because it would explain why the chelate seems less affected by inhibitors, but direct human proof is lacking, and it remains a hypothesis. Most reviewers conclude that the chelate probably delivers iron mainly by the regulated route, with some added protection in the lumen.

Protection in the lumen is the key proposed advantage. Phytate in grains and legumes, polyphenols in tea and coffee, and calcium in dairy bind free ferrous iron and make it unavailable. Meal studies in humans found that absorption from bisglycinate was less reduced by phytate and polyphenols than absorption from ferrous sulfate. Milk still reduced absorption of bisglycinate, and vitamin C increased it, so the chelate is not immune to these influences. The effect is a matter of degree.

Stomach acid adds another layer. Acid helps keep non-heme iron soluble and reduces ferric iron toward the ferrous form, so medicines that lower acid, such as proton pump inhibitors, tend to reduce absorption of ordinary iron salts. Because a chelate is held together by its own bonds, it has been suggested that bisglycinate depends less on acid to stay soluble. This is a theoretical benefit, and direct comparisons in people taking acid-reducing drugs are scarce.

5. Pathway 2: Transport and use in red blood cell production

After crossing the intestinal cell, iron is either stored there as ferritin or exported into the blood through the protein ferroportin on the cell's inner surface. The enzyme hephaestin, with help from ceruloplasmin, oxidizes ferrous iron to ferric iron so that it can attach to transferrin, the main iron carrier in plasma.

Transferrin delivers iron to cells that display the transferrin receptor, known as TfR1. The receptor and its iron cargo are taken into the cell inside a vesicle. Acidification of the vesicle releases iron, and the iron is reduced and moved into the cytoplasm by DMT1. The receptor is then recycled to the cell surface.

Developing red blood cells in the bone marrow have the most TfR1 and use most of the body's iron, about two thirds of the total. In their mitochondria, the enzyme ferrochelatase inserts ferrous iron into protoporphyrin IX to make heme, which is then combined with globin to form hemoglobin. When iron is short, red cells are made smaller and paler, and hemoglobin falls. Replenishing iron restores this pathway, which is why the first measurable response to iron treatment is often a rise in reticulocytes and then in hemoglobin.

The timeline of response reflects this pathway. Within about a week of starting effective treatment, the marrow releases more young red cells, called reticulocytes. Hemoglobin then climbs over the following weeks, and ferritin, which reflects stored iron, recovers last. A rise in hemoglobin without a rise in ferritin suggests that new iron is being used as fast as it arrives, and not yet stored.

This pathway is identical for all iron supplements. The only difference bisglycinate could make is in how much iron reaches the blood.

6. Pathway 3+: Storage, regulation and iron-dependent enzymes

Pathway 3: Storage and recycling

Excess iron is stored in ferritin, a hollow protein shell that can hold thousands of iron atoms in a safe, non-reactive form. Most storage is in the liver and in macrophages of the spleen and bone marrow. Macrophages also recycle iron from old red blood cells, which supplies most of the iron the body needs each day. Serum ferritin, which leaks into the blood in proportion to stores, is the main laboratory marker of iron status.

Pathway 4: Systemic regulation by hepcidin

Hepcidin, a hormone made in the liver, controls how much iron enters the blood. It binds ferroportin and causes it to be taken into the cell and degraded, which traps iron inside intestinal cells and macrophages. High iron and inflammation raise hepcidin. Iron deficiency, low oxygen and active red cell production lower it.

Hepcidin also helps explain dosing patterns. Stable-isotope studies show that a dose of oral iron raises hepcidin within hours, and that hepcidin stays elevated for about a day, which reduces absorption of a dose taken soon afterward. This applies to iron generally, and specific data on bisglycinate are limited.

If bisglycinate triggers a smaller hepcidin response than a large dose of ferrous sulfate, that could help explain why lower bisglycinate doses perform well in some trials. Dose size is the more likely driver, since any form given in a big enough dose raises hepcidin, and head-to-head hepcidin data for the two forms are scarce.

Pathway 5: Iron-dependent enzymes and mitochondria

Iron is a cofactor for hundreds of proteins. These include the cytochromes and iron-sulfur proteins in the mitochondrial electron transport chain, which make cellular energy, ribonucleotide reductase, which is needed for DNA synthesis, and myoglobin, which stores oxygen in muscle. Iron deficiency impairs these functions even before anemia develops, which may help explain fatigue in people with low ferritin and normal hemoglobin.

Pathway 6: Events in the gut lumen

Iron that is not absorbed travels to the colon. There it can change the microbial community and irritate the lining. In a trial in Kenyan infants, iron-containing fortification shifted the gut bacteria toward more potential pathogens and increased signs of intestinal inflammation. Whether a chelate that lowers free iron in the lumen has a milder effect is a hypothesis, supported by some clinical tolerability data but not yet by direct microbiome studies in people.

7. Cellular signaling

Iron does not act through a classic signaling receptor, but cells sense it and adjust their behavior through several signaling systems.

•      Iron regulatory proteins (IRP1 and IRP2): These proteins bind to stem-loop sequences called iron-responsive elements in messenger RNA. When iron is low, they block production of ferritin and ferroportin and stabilize the mRNA for TfR1, so cells take up more iron and store less. When iron is plentiful, the effect reverses.

•      Hepcidin regulation: In liver cells, iron levels signal through the BMP6 and SMAD pathway, and inflammation signals through interleukin-6 and the JAK/STAT3 pathway, to adjust hepcidin production.

•      Oxygen-sensing enzymes: Prolyl hydroxylases that control hypoxia-inducible factors need ferrous iron as a cofactor. Iron status therefore interacts with the body's response to low oxygen, including production of erythropoietin.

•      Heme and erythropoiesis: Heme availability regulates its own synthesis, partly through an iron-responsive element in the mRNA for ALAS2, the first enzyme in heme production in red cells.

An important consequence is that iron supplementation changes these signals. As iron stores rise, IRP activity falls, hepcidin rises and absorption declines. These are the same feedback loops that make dose-response with oral iron non-linear.

8. Oxidative stress pathways

Iron's usefulness comes from its ability to gain and lose electrons, and the same property makes it hazardous when it is free. Free ferrous iron can react with hydrogen peroxide in the Fenton reaction to produce hydroxyl radicals, which damage lipids, proteins and DNA. For this reason the body keeps iron tightly bound to transferrin and ferritin and maintains only a small pool of loosely bound, or labile, iron in cells.

Oxidative stress has two sides in iron biology. In iron deficiency, antioxidant enzymes that contain heme, such as catalase, work less well, and mitochondria can produce more reactive oxygen. In iron excess, free iron promotes lipid peroxidation, and a form of cell death called ferroptosis, driven by iron-dependent lipid peroxidation, has been linked to tissue damage in laboratory models. These excess-iron effects are mainly relevant to overload conditions and not to ordinary supplement doses.

In the gut, unabsorbed ferrous iron can generate radicals at the mucosal surface. A chelate may keep more of the iron bound until it is absorbed, which could reduce this effect. Some animal studies have reported less oxidative damage with iron chelates than with ferrous sulfate, but human data are limited and mixed. At present, the oxidative-stress advantage of bisglycinate is a plausible hypothesis, not an established property.

Vitamin C illustrates the double-edged nature of redox chemistry. In the gut it helps absorption by keeping iron ferrous, but in laboratory systems ascorbate together with free iron can also generate radicals. In the body, tightly controlled binding proteins make this a minor concern at ordinary intakes, though it is one reason vitamin C supplements are not advised in people with iron overload.

9. Inflammatory pathways if relevant

Inflammation and iron are closely linked. Interleukin-6 and other inflammatory signals raise hepcidin, which lowers iron in the blood and traps it in macrophages. This is part of the body's defense, sometimes called nutritional immunity, because many pathogens need iron to grow. The result is anemia of inflammation, in which iron is present in stores but unavailable for red cell production.

This pathway has practical consequences. When hepcidin is high because of inflammation, oral iron is poorly absorbed, whatever the form. This is one explanation for the neutral result of oral iron in the IRONOUT HF heart failure trial. It also means ferritin can look normal in people with inflammation even when functional iron is low.

Iron also affects immune cells directly. Iron deficiency impairs the growth of lymphocytes and the killing function of neutrophils, while iron excess may favor pathogen growth. This is the mechanistic background for caution about iron in young children in areas with high malaria transmission, as seen in the Pemba trial. No bisglycinate-specific inflammatory mechanism has been established.

10. Endocrine/neurotransmitter/metabolic pathways if relevant

Beyond blood, iron participates in several metabolic and signaling systems.

•      Dopamine and serotonin: Tyrosine hydroxylase and tryptophan hydroxylase require iron as a cofactor, linking iron status to the synthesis of dopamine and serotonin. Iron is also needed for myelin formation in the developing brain. These roles help explain research on iron and cognition and on conditions such as restless legs, but the supplement evidence is mixed.

•      Thyroid hormone: Thyroid peroxidase is a heme-containing enzyme, so iron deficiency can impair thyroid hormone synthesis.

•      Energy metabolism: Iron-sulfur clusters and cytochromes carry electrons in the respiratory chain, and iron is needed for aconitase in the citric acid cycle.

•      Hormones that regulate iron: Erythropoietin controls red cell production and responds to oxygen through iron-dependent sensors, and hepcidin acts as an endocrine regulator of iron supply.

•      Glycine as a neurotransmitter: Glycine acts as an inhibitory neurotransmitter and a co-agonist at NMDA receptors. The glycine delivered by an iron supplement is far below the amounts used in glycine research, so no neurotransmitter effect is expected.

11. Mechanism diagram

The diagram shows the proposed route of iron bisglycinate from supplement to target cell, including the hepcidin feedback loop and the effects of unabsorbed iron in the gut. It is simplified and is intended as a map, not a complete model.

Reading the diagram: Steps 1 to 3 are where bisglycinate may differ from other iron forms. Steps 4 to 7 are the same for every form of iron. The dashed lines show the main regulation, with hepcidin limiting how much iron leaves the intestinal cell, and unabsorbed iron producing possible local effects in the colon.

12. Preclinical evidence

Preclinical research, meaning cell and animal studies, supports several parts of the proposed mechanism but cannot settle them.

•      Chemistry and stability: Laboratory work shows that ferrous bisglycinate holds together across a range of acidity found in the stomach and intestine, which supports the idea of lumen protection.

•      Absorption in animals: Studies in rats have reported good absorption and repletion of hemoglobin with iron amino acid chelates, and some have reported advantages over ferrous sulfate. These findings depend on the species, the diet and the iron status of the animals.

•      Cell models: Intestinal cell cultures have been used to study iron uptake from chelates, with results that vary by model and do not establish whether the intact chelate is taken up.

•      Toxicology: A safety evaluation of ferrous bisglycinate in animals supported its safety at the doses tested.

•      Oxidative and gut effects: Some animal studies suggest chelates cause less intestinal oxidative damage, but the findings are limited.

Animals differ from people in diet, gut acidity and iron regulation, so these studies are best seen as generating hypotheses and not as proof.

Preclinical work also shows how strongly iron handling depends on context. Animals made iron deficient absorb far more iron than replete animals, and inflammation lowers absorption by raising hepcidin. Results from an iron-deficient rat do not necessarily apply to a healthy person with full stores, which is a reason to examine the participant's iron status in every study.

13. Human relevance

Human studies connect the mechanisms to real outcomes in a few specific ways.

•      Regulation by iron status: A stable-isotope study found that absorption of iron from bisglycinate in maize meals was regulated by iron status, which supports absorption through a regulated pathway.

•      Resistance to inhibitors: Breakfast studies found less inhibition of bisglycinate by phytate and polyphenols than of ferrous sulfate, while milk still reduced it and vitamin C still enhanced it.

•      Efficacy at lower doses: A randomized trial in pregnant women found that 25 mg of iron as bisglycinate performed as well as 50 mg as ferrous sulfate in preventing iron deficiency and anemia, with fewer gastrointestinal complaints. A study in infants and young children reported effective treatment of anemia, and a 2023 meta-analysis of randomized trials concluded that bisglycinate improves hemoglobin and ferritin, though with low-certainty evidence.

•      Tolerability: Fewer side effects were reported in some trials. The mechanism is not proven, and could relate to lower iron doses, lower free iron in the gut or other factors.

The post-absorption pathways described in sections 5 to 10 are well established in humans and apply to all iron forms. The bisglycinate-specific steps in section 4 are the part with the least direct human evidence.

Human trials also have limits that matter for mechanism. Many used small samples, many compared products at different elemental doses, and many measured laboratory endpoints and not symptoms. A trial that finds equal results at half the dose cannot show by itself whether absorption, tolerability or adherence explains the result, which is why mechanism and outcome evidence should be read together.

Mechanistic claim	Evidence in humans	Overall support
Iron from bisglycinate follows the normal iron pathways after absorption	Extensive knowledge of iron physiology	Strong
Absorption is regulated by iron status	Stable-isotope study in humans	Moderate
Less inhibited by phytate and polyphenols than ferrous sulfate	Meal absorption studies	Moderate
Effective at lower elemental doses	One randomized pregnancy trial and a meta-analysis with low-certainty evidence	Moderate to limited
Gentler on the gut because of lower free iron	Some trials report fewer side effects; mechanism unproven	Limited
Intact chelate absorbed through amino acid or peptide transporters	No direct human evidence	Weak
Less oxidative stress or microbiome disruption	Mainly animal and chemical data	Weak

 

14. Mechanistic uncertainty

Several important questions remain open, and readers should treat claims about bisglycinate's mechanism with caution.

•      How much of the chelate stays intact: It is not clear what fraction survives to the intestinal cell, and it likely varies with stomach acid, food and dose.

•      Whether intact chelate is taken up: Uptake through amino acid or peptide transporters has been proposed but is not demonstrated in humans.

•      Dose equivalence: If lower doses of bisglycinate match higher doses of ferrous sulfate, the reason could be better absorption, better adherence, or both. Trials rarely separate these.

•      Hepcidin response: Data on how hepcidin responds to bisglycinate, compared with other forms, are limited. If a smaller dose triggers a smaller hepcidin rise, it could explain the results, but this is not shown.

•      Gut and microbiome effects: Direct human data on bisglycinate and the microbiome are lacking.

•      Oxidative stress: The claimed antioxidant advantage rests mostly on animal and chemical data.

•      Product differences: Ingredient suppliers differ in iron content, purity and process, and results from one product may not carry over to another.

•      Study limitations: Many trials are small, short, or comparator-limited, and some had links to the ingredient industry.

Overall, the evidence supports iron bisglycinate as a plausible, well-tolerated source of iron whose basic biology is the same as other iron forms. Claims that it is absorbed by a unique pathway, or that it is clearly superior to other forms, go beyond what current research shows. Anyone considering iron should seek professional advice and a blood test first.

15. References

1.      Hertrampf E, Olivares M. Iron amino acid chelates. Int J Vitam Nutr Res. 2004;74:435-443.

2.      Bovell-Benjamin AC, Viteri FE, Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr. 2000;71:1563-1569.

3.      Layrisse M, García-Casal MN, Solano L, et al. Iron bioavailability in humans from breakfasts enriched with iron bis-glycine chelate, phytates and polyphenols. J Nutr. 2000;130:2195-2199.

4.      Olivares M, Pizarro F, Pineda O, Name JJ, Hertrampf E, Walter T. Milk inhibits and ascorbic acid favors ferrous bis-glycine chelate bioavailability in humans. J Nutr. 1997;127:1407-1411.

5.      Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG. Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. J Perinat Med. 2014;42:197-206.

6.      Pineda O, Ashmead HD. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17:381-384.

7.      Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD. The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2023;81:904-920.

8.      Ashmead HD. The absorption and metabolism of iron amino acid chelate. Arch Latinoam Nutr. 2001;51(1 Suppl 1):13-21.

9.      Jeppsen RB, Borzelleca JF. Safety evaluation of ferrous bisglycinate chelate. Food Chem Toxicol. 1999;37:723-731.

10.   Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126:1981-1989.

11.   Jaeggi T, Kortman GAM, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64:731-742.

12.   Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317:1958-1966.

13.   Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet. 2006;367:133-143.

14.   Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823:1434-1443.

15.   Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397:233-248.